NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Consensus Recommendation of “Hold” from Analysts

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have earned a consensus recommendation of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $11.90.

Several analysts recently weighed in on NMTC shares. Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. JonesTrading started coverage on NeuroOne Medical Technologies in a report on Monday, March 2nd. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Zacks Research downgraded NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th.

Insider Buying and Selling at NeuroOne Medical Technologies

In other news, insider David J. Wambeke acquired 166,666 shares of the firm’s stock in a transaction that occurred on Sunday, March 1st. The stock was purchased at an average cost of $4.02 per share, for a total transaction of $669,997.32. Following the completion of the acquisition, the insider directly owned 166,666 shares of the company’s stock, valued at $669,997.32. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 2,438 shares of company stock valued at $11,702 in the last ninety days. Insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Several institutional investors and hedge funds have recently made changes to their positions in NMTC. Goldman Sachs Group Inc. bought a new stake in shares of NeuroOne Medical Technologies in the first quarter valued at about $84,000. XTX Topco Ltd bought a new stake in shares of NeuroOne Medical Technologies in the second quarter valued at about $51,000. Focus Financial Network Inc. bought a new stake in shares of NeuroOne Medical Technologies in the third quarter valued at about $31,000. Vanguard Group Inc. raised its holdings in shares of NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after acquiring an additional 375,639 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in NeuroOne Medical Technologies in the third quarter valued at about $88,000. 16.07% of the stock is currently owned by institutional investors.

NeuroOne Medical Technologies Stock Up 2.9%

NMTC stock opened at $4.98 on Tuesday. The business’s fifty day simple moving average is $4.47 and its two-hundred day simple moving average is $4.64. NeuroOne Medical Technologies has a twelve month low of $3.21 and a twelve month high of $6.96. The firm has a market cap of $41.93 million, a price-to-earnings ratio of -4.88 and a beta of 0.63.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, February 17th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.The business had revenue of $2.89 million for the quarter, compared to analyst estimates of $2.47 million. Research analysts expect that NeuroOne Medical Technologies will post -0.72 EPS for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.